NCT06258525 2026-03-18
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting
Clinical Trials
701 trialsNCT07478731 2026-03-17
MA-CRC-II-018
Tongji Hospital
Phase 2 Recruiting
NCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT07467590 2026-03-12
TRIUNITE-07
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT03654131 2026-03-11
LAVA-CRLM
Rigshospitalet, Denmark
Phase 2 Active not recruiting
NCT04705818 2026-03-06
CAIRE
Institut Bergonié
Phase 2 Completed
NCT05343013 2026-03-06
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07432399 2026-03-06
PILDI
Institute of Oncology Ljubljana
Phase 2 Recruiting
NCT06528990 2026-03-05
Telehealth Intervention for Ostomy Self-Management
City of Hope Medical Center
Phase 2 Recruiting
NCT07448142 2026-03-04
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
NCT07446387 2026-03-03
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Not yet recruiting
NCT07447050 2026-03-03
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
Phase 2 Recruiting
NCT04771520 2026-03-02
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07136077 2026-02-27
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06356597 2026-02-24
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT05677113 2026-02-23
PERIOP-06
Sunnybrook Health Sciences Centre
Phase 2 Active not recruiting
NCT06130280 2026-02-18
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02738606 2026-02-17
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT07071961 2026-02-17
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT07405736 2026-02-12
Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
NCT06558773 2026-02-11
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07403877 2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2 Not yet recruiting
NCT04963283 2026-02-10
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT06728072 2026-02-09
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Virginia Commonwealth University
Phase 2 Recruiting
NCT00556413 2026-02-05
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT01815359 2026-02-05
ICARuS
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06617858 2026-02-05
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04787341 2026-02-02
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT06553885 2026-01-29
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07371273 2026-01-27
Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR
Fudan University
Phase 2 Recruiting
NCT05954429 2026-01-22
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
Fudan University
Phase 2 Recruiting
NCT07359456 2026-01-22
COLIBRI-GI
UNICANCER
Phase 2 Not yet recruiting
NCT04767984 2026-01-21
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
Northwestern University
Phase 2 Active not recruiting
NCT07353268 2026-01-20
Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07042685 2026-01-16
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT06129604 2026-01-15
Pilot Window of Opportunity Trial (POET)
University of Oklahoma
Phase 2 Active not recruiting
NCT00335816 2026-01-14
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07337551 2026-01-13
Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive
The Second Hospital of Hebei Medical University
Phase 2 Not yet recruiting
NCT03087071 2026-01-12
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07333651 2026-01-12
125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer
Jinan Military General Hospital
Phase 2 Not yet recruiting
NCT03599752 2026-01-09
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07229846 2026-01-08
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Phase 2 Not yet recruiting
NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
NCT06578559 2026-01-05
BRICKET
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT04779554 2025-12-24
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
University of Kentucky
Phase 2 Recruiting